Science
Brazil's health regulator Anvisa is authorizing a Chinese COVID-19 vaccine trial
According to the publication of an Official Gazette, on Fridays the Brazilian Health Regulator Anvisa approved clinical studies on a potential Chinese Sinovac Coronavirus vaccine.
The study, first announced on 11 June, is led by the Butantan Institute, a São Paulo state-funded research center. Not only trials but the technological transfer of potential vaccine locally are covered in the agreement with Sinovac.
Governor Joao Doria of Sao Paulo stated on 29 June that 9 000 volunteers were registered for the testing of COVID-19, a novel coronavirus respirative disease vaccine.
12 research centers in six states in Brazil will carry out trials, according to Doria, such as Sao Paulo, Rio de Janeiro, Minas Gerais, Brasilia, Rio Grande do sul and Parana.
According to Health Ministry data, the second worst outbreak after the United States, Brazil has over 1.5 million confirmed cases of VOCID-19. In the last 24 hours, the number of fatalities increased by 1,290, bringing the total to 63,174, according to the data.
Source: Reuters; Reporting by Eduardo Simoes and Gabriela Mello; Editing by Christian Schmollinger
